Bramlage, Carsten

[["dc.bibliographiccitation.firstpage","e0222102"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Grupp, Clemens"],["dc.contributor.author","Troche-Polzien, Ilka"],["dc.contributor.author","Stock, Johanna"],["dc.contributor.author","Bramlage, Carsten"],["dc.contributor.author","Müller, Gerhard A."],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.editor","Gonzalez Suarez, Maria Lourdes"],["dc.date.accessioned","2020-12-10T18:42:10Z"],["dc.date.available","2020-12-10T18:42:10Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1371/journal.pone.0222102"],["dc.identifier.eissn","1932-6203"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16604"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77833"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Thrombophilic risk factors in hemodialysis: Association with early vascular access occlusion and patient survival in long-term follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","480"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Research Notes"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Bramlage, Carsten P."],["dc.contributor.author","Nasiri-Sarvi, Mina"],["dc.contributor.author","Minguet, Joan"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Müller, Gerhard A."],["dc.date.accessioned","2019-07-09T11:42:51Z"],["dc.date.available","2019-07-09T11:42:51Z"],["dc.date.issued","2016"],["dc.description.abstract","Abstract Background and aims Arterial hypertension is a major cause of death worldwide. For the most part, treatment for hypertension can be performed on an outpatient basis. However, some patients also require inpatient treatment, and the contributing factors for this remain unknown. Therefore, the primary objective of the present study was to determine which patient characteristics are associated with inpatient treatment for arterial hypertension. Methods Here, we conducted a mono-centric study of 103 hypertensive subjects, who were treated as inpatients in the Department of Nephrology and rheumatology of the university medical faculty of Göttingen. Therapies were not altered, and data collection was performed retrospectively. In addition to epidemiological information, the following data were recorded: patient symptoms, blood pressure (BP), anti-hypertensive therapy, and concomitant diseases (e.g., renal and cardiovascular conditions). Results Approximately half (53 %) of all subjects treated on an inpatient basis displayed elevated BP (>140/90 mmHg), while the remaining 47 % of patients showed normotensive readings (<140/90 mmHg) following admission. Moreover, 34 % of patients could be classified as therapy refractory. The main reasons for hospital admission were hypertension-related symptoms, including shortness of breath, dizziness, and headache (69 %). These patients were multi-morbid, with approximately 60 % displaying a secondary form of hypertension. Indeed, over half of the subjects showed renoparenchymatous forms of hypertension, and a large percentage of patients received hypertension-inducing drugs (32 %). Moreover, a high proportion of inpatients were treated with reserve antihypertensives, with the most commonly used drug being Moxonidin. Conclusion The majority of hypertensive patients were hospitalized due to their clinical symptoms and not as a result of BP values alone. The high proportion of patients with secondary forms of hypertension or treated with BP-boosting medications was striking."],["dc.identifier.doi","10.1186/s13104-016-2285-y"],["dc.identifier.pmid","27776558"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13901"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58767"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Characterization and history of arterial hypertension leading to inpatient treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1115"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Hypertension"],["dc.bibliographiccitation.lastpage","1122"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Pryce, Christopher Robert"],["dc.contributor.author","Mirza, Serkan"],["dc.contributor.author","Schnell, Christian"],["dc.contributor.author","Amann, Kerstin"],["dc.contributor.author","Amstrong, Victor William"],["dc.contributor.author","Eitner, Frank"],["dc.contributor.author","Zapf, Antonia"],["dc.contributor.author","Feldon, Joram"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Fuchs, Eberhard"],["dc.contributor.author","Mueller, Gerhard Anton"],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T11:22:44Z"],["dc.date.available","2018-11-07T11:22:44Z"],["dc.date.issued","2009"],["dc.description.abstract","The influence of prenatal factors on the development of arterial hypertension has gained considerable interest in recent years. Prenatal dexamethasone exposure was found to induce hypertension and to alter nephron number and size in rodents and sheep. However, it is not clear whether these findings are applicable to nonhuman primates. Thus, we examined the effects of prenatal dexamethasone treatment on blood pressure (BP) and nephron number in marmoset monkeys. Fifty-two marmosets were allotted to 3 groups according to the gestational stage during which their mothers were exposed to oral 5-mg/kg dexamethasone for 7 days (gestation period: 20 weeks): (1) the early dexamethasone group at week 7; (2) the late dexamethasone group at week 13; and (3) the control group. BP was determined by telemetric (n = 12) or cuff measurements (n = 30), along with cystatin C, proteinuria, and body weight. All of the animals were euthanized at the age of 24 months, and glomerular number and volume were determined. Prenatal exposure to dexamethasone did not lead to a significant difference between the groups with regard to BP, kidney morphology and function, or body weight. BP correlated significantly with body weight, relative kidney weight, and mean glomerular volume and the body weight with the glomerular volume regardless of dexamethasone treatment. In conclusion, prenatal exposure to dexamethasone in marmosets does not, in contrast to other mammals studied, result in hypertension or changes in kidney morphology. Our data support the role of body weight as a predictor of elevated glomerular volume and BP development rather than prenatal dexamethasone exposure. (Hypertension. 2009;54:1115-1122.)"],["dc.identifier.doi","10.1161/HYPERTENSIONAHA.109.136580"],["dc.identifier.isi","000270992100031"],["dc.identifier.pmid","19770406"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6183"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56040"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0194-911X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Prenatal Dexamethasone Exposure Does Not Alter Blood Pressure and Nephron Number in the Young Adult Marmoset Monkey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","31"],["dc.bibliographiccitation.journal","BMC Nephrology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Tampe, Bjoern"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Maatouk, Imad"],["dc.contributor.author","Bevanda, Jelena"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Ahrens, Katharina"],["dc.contributor.author","Lange, Katharina"],["dc.contributor.author","Schmid, Holger"],["dc.contributor.author","Cohen, Clemens D."],["dc.contributor.author","Kretzler, Matthias"],["dc.contributor.author","Mueller, Georg Anton"],["dc.date.accessioned","2018-11-07T08:36:49Z"],["dc.date.available","2018-11-07T08:36:49Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Bone Morphogenetic Protein (BMP)-7 is protective in different animal models of acute and chronic kidney disease. Its role in human kidneys, and in particular hypertensive nephrosclerosis, has thus far not been described. Methods: BMP-7 mRNA was quantified using real-time PCR and localised by immunostaining in tissue samples from normal and nephrosclerotic human kidneys. The impact of angiotensin (AT)-II and the AT-II receptor antagonist telmisartan on BMP-7 mRNA levels and phosphorylated Smad 1/5/8 (pSmad 1/5/8) expression was quantified in proximal tubular cells (HK-2). Functional characteristics of BMP-7 were evaluated by testing its influence on TGF-beta induced epithelial-to-mesenchymal transition (EMT), expression of TGF-beta receptor type I (TGF-beta RI) and phosphorylated Smad 2 (pSmad 2) as well as on TNF-alpha induced apoptosis of proximal tubular cells. Results: BMP-7 was predominantly found in the epithelia of the distal tubule and the collecting duct and was less abundant in proximal tubular cells. In sclerotic kidneys, BMP-7 was significantly decreased as demonstrated by real-time PCR and immunostaining. AT-II stimulation in HK-2 cells led to a significant decrease of BMP-7 and pSmad 1/5/8, which was partially ameliorated upon co-incubation with telmisartan. Only high concentrations of BMP-7 (100 ng/ml) were able to reverse TNF-alpha-induced apoptosis and TGF-beta-induced EMT in human proximal tubule cells possibly due to a decreased expression of TGF-beta RI. In addition, BMP-7 was able to reverse TGF-beta-induced phosphorylation of Smad 2. Conclusions: The findings suggest a protective role for BMP-7 by counteracting the TGF-beta and TNF-alpha-induced negative effects. The reduced expression of BMP-7 in patients with hypertensive nephrosclerosis may imply loss of protection and regenerative potential necessary to counter the disease."],["dc.identifier.doi","10.1186/1471-2369-11-31"],["dc.identifier.isi","000208334700001"],["dc.identifier.pmid","21080950"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5802"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18396"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2369"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Bone Morphogenetic Protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","R58"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Arthritis Research & Therapy"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Haupl, Thomas"],["dc.contributor.author","Kaps, Christian"],["dc.contributor.author","Ungethum, Ute"],["dc.contributor.author","Krenn, Veit"],["dc.contributor.author","Pruss, Axel"],["dc.contributor.author","Mueller, Gerhard A."],["dc.contributor.author","Strutz, Frank M."],["dc.contributor.author","Burmester, Gerd-R."],["dc.date.accessioned","2018-11-07T10:29:49Z"],["dc.date.available","2018-11-07T10:29:49Z"],["dc.date.issued","2006"],["dc.description.abstract","Bone morphogenetic proteins (BMPs) have been identified as important morphogens with pleiotropic functions in regulating the development, homeostasis and repair of various tissues. The aim of this study was to characterize the expression of BMPs in synovial tissues under normal and arthritic conditions. Synovial tissue from normal donors (ND) and from patients with osteoarthritis (OA) and rheumatoid arthritis (RA) were analyzed for BMP expression by using microarray hybridization. Differential expression of BMP-4 and BMP-5 was validated by semiquantitative RT-PCR, in situ hybridization and immunohistochemistry. Activity of arthritis was determined by routine parameters for systemic inflammation, by histological scoring of synovitis and by semiquantitative RT-PCR of IL-1 beta, TNF-alpha, stromelysin and collagenase I in synovial tissue. Expression of BMP-4 and BMP-5 mRNA was found to be significantly decreased in synovial tissue of patients with RA in comparison with ND by microarray analysis ( p < 0.0083 and p < 0.0091). Validation by PCR confirmed these data in RA ( p < 0.002) and also revealed a significant decrease in BMP-4 and BMP-5 expression in OA compared with ND ( p < 0.015). Furthermore, histomorphological distribution of both morphogens as determined by in situ hybridization and immunohistochemistry showed a dominance in the lining layer of normal tissues, whereas chronically inflamed tissue from patients with RA revealed BMP expression mainly scattered across deeper layers. In OA, these changes were less pronounced with variable distribution of BMPs in the lining and sublining layer. BMP-4 and BMP-5 are expressed in normal synovial tissue and were found decreased in OA and RA. This may suggest a role of distinct BMPs in joint homeostasis that is disturbed in inflammatory and degenerative joint diseases. In comparison with previous reports, these data underline the complex impact of these factors on homeostasis and remodeling in joint physiology and pathology."],["dc.identifier.doi","10.1186/ar1923"],["dc.identifier.isi","000237649000010"],["dc.identifier.pmid","16542506"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/1245"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43724"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1478-6354"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]